Literature DB >> 26125504

Did we abandon probucol too soon?

Shizuya Yamashita1, Daisaku Masuda, Yuji Matsuzawa.   

Abstract

PURPOSE OF REVIEW: Probucol is a potent antioxidative drug that has been used for prevention and treatment of atherosclerotic cardiovascular diseases and xanthoma. Probucol has been used as a lipid-lowering drug for a long time especially in Japan, although Western countries quitted its use because of the reduction in serum HDL-cholesterol (HDL-C). This review highlights both basic and clinical studies that provide new insights into the pleiotropic effects of probucol. RECENT
FINDINGS: Recently, the mechanisms for the pharmacologic actions of probucol have been elucidated at the molecular level with a special focus on HDL metabolism and its functions. Probucol enhances plasma cholesteryl ester transfer protein activity and hepatic scavenger receptor class B type I, causing a decrease in HDL-C. It also accelerates the antioxidative function of HDL via increase in paraoxonase 1 activity. Recent retrospective analyses of probucol-treated patients with heterozygous familial hypercholesterolemia and those after coronary revascularization demonstrated a strong beneficial effect of probucol on secondary prevention of cardiovascular events and mortality.
SUMMARY: Probucol has pleiotropic and beneficial therapeutic effects on cardiovascular system. Although statins are effective for lowering LDL-cholesterol (LDL-C) and reducing coronary heart disease risk, probucol should be considered as an option in case statins are not effective.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26125504     DOI: 10.1097/MOL.0000000000000199

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  14 in total

1.  Targeted Deletion of Hepatocyte Abca1 Increases Plasma HDL (High-Density Lipoprotein) Reverse Cholesterol Transport via the LDL (Low-Density Lipoprotein) Receptor.

Authors:  Alexander C Bashore; Mingxia Liu; Chia-Chi C Key; Elena Boudyguina; Xianfeng Wang; Caitlin M Carroll; Janet K Sawyer; Adam E Mullick; Richard G Lee; Shannon L Macauley; John S Parks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06-06       Impact factor: 8.311

2.  High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

Authors:  Arnold von Eckardstein
Journal:  Handb Exp Pharmacol       Date:  2022

3.  Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells.

Authors:  Aslı Koç; Arzu Zeynep Karabay; Ali Yaprak; Zeliha Büyükbingöl; Fügen Aktan
Journal:  Turk J Pharm Sci       Date:  2021-02-25

4.  Lipolysis stimulating peptides of potato protein hydrolysate effectively suppresses high-fat-diet-induced hepatocyte apoptosis and fibrosis in aging rats.

Authors:  Wen-Dee Chiang; Chih Yang Huang; Catherine Reena Paul; Zong-Yan Lee; Wan-Teng Lin
Journal:  Food Nutr Res       Date:  2016-07-12       Impact factor: 3.894

5.  Effects of probucol on atherosclerotic plaque and soluble thrombomodulin in patients with coronary heart disease.

Authors:  Donghai Liu; Guoping Yang; Xuebin Zhao; Huanzhi Yang
Journal:  Exp Ther Med       Date:  2018-06-07       Impact factor: 2.447

6.  New Probucol Analogues Inhibit Ferroptosis, Improve Mitochondrial Parameters, and Induce Glutathione Peroxidase in HT22 Cells.

Authors:  Diones Caeran Bueno; Rômulo Faria Santos Canto; Viviane de Souza; Rafaela Rafognatto Andreguetti; Flávio Augusto Rocha Barbosa; Aline Aita Naime; Partha Narayan Dey; Verena Wüllner; Mark William Lopes; Antônio Luiz Braga; Axel Methner; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2020-06-08       Impact factor: 5.682

7.  Probucol Protects Rats from Cardiac Dysfunction Induced by Oxidative Stress following Cardiopulmonary Resuscitation.

Authors:  Xu Xiao; Huiyuan Hou; Victor Lin; Daisy Ho; Kyle Tran; Briana Che; Adam May; Jiancheng Zhang; Zhigang Lu; Zhongping Lu; Peter X Shaw
Journal:  Oxid Med Cell Longev       Date:  2017-10-30       Impact factor: 6.543

8.  Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease.

Authors:  Cristine de Paula Nascimento-Castro; Ana Claudia Wink; Victor Silva da Fônseca; Claudia Daniele Bianco; Elisa C Winkelmann-Duarte; Marcelo Farina; Ana Lúcia S Rodrigues; Joana Gil-Mohapel; Andreza Fabro de Bem; Patricia S Brocardo
Journal:  Neural Plast       Date:  2018-08-14       Impact factor: 3.599

9.  Probucol Prevents Diabetes-Induced Retinal Neuronal Degeneration through Upregulating Nrf2.

Authors:  Heng-Wei Liu; Yong Luo; Yu-Fan Zhou; Zhong-Ping Chen
Journal:  Biomed Res Int       Date:  2020-02-13       Impact factor: 3.411

10.  Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.

Authors:  Takeshi Okada; Mizuki Sumida; Tohru Ohama; Yuki Katayama; Ayami Saga; Hiroyasu Inui; Kotaro Kanno; Daisaku Masuda; Masahiro Koseki; Makoto Nishida; Yasushi Sakata; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2020-10-17       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.